Literature DB >> 2801715

Multidisciplinary program for detecting and evaluating adverse drug reactions.

M R Keith1, R A Bellanger-McCleery, J E Fuchs.   

Abstract

An adverse drug reaction (ADR)-reporting program involving detection of charted ADRs by quality assurance nurses and data collection and causality assessment by staff pharmacists is described. The voluntary ADR-reporting mechanism used in a 900-bed, university-based hospital complex produced less than one ADR report per month. The newly implemented system depends on nurses to detect and report documented ADRs through concurrent chart review. Staff pharmacists are then responsible for follow-up chart review, data collection, and causality assignment based on two published algorithms. An inservice education program designed to increase the awareness and understanding of ADRs was provided to the department of pharmacy and the quality assurance nurses. The clinical staff provides quality assurance through weekly ADR committee meetings. Drug information center personnel complete the causality algorithms by using the data collected by the staff pharmacists. The ADR committee then compares the algorithm results of the two assessors. Discrepancies in scoring are evaluated to determine whether a change in the system is necessary. An FDA report is generated if the staff pharmacist assessor and the drug information center assessor obtain results of "probable" for both algorithms. An ADR-reporting program that relies on quality assurance nurses to detect charted ADRs and on staff pharmacists to evaluate reported ADRs increased the average number of ADRs reported from 0.4 to 20 per month.

Mesh:

Year:  1989        PMID: 2801715

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  9 in total

1.  Academic detailing improves identification and reporting of adverse drug events.

Authors:  R G Schlienger; T F Lüscher; R A Schoenenberger; W E Haefeli
Journal:  Pharm World Sci       Date:  1999-06

2.  Development of a trigger tool for the detection of adverse drug events in Chinese geriatric inpatients using the Delphi method.

Authors:  Qiaozhi Hu; Zhou Qin; Mei Zhan; Bin Wu; Zhaoyan Chen; Ting Xu
Journal:  Int J Clin Pharm       Date:  2019-06-28

3.  Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: A prospective, descriptive, observational study.

Authors:  Agnes L F Chan; Haw Yu Lee; Chi-Hou Ho; Thau-Ming Cham; Shun Jin Lin
Journal:  Curr Ther Res Clin Exp       Date:  2008-04

4.  Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report.

Authors:  A K Jha; G J Kuperman; J M Teich; L Leape; B Shea; E Rittenberg; E Burdick; D L Seger; M Vander Vliet; D W Bates
Journal:  J Am Med Inform Assoc       Date:  1998 May-Jun       Impact factor: 4.497

5.  Incidence and preventability of adverse drug events in hospitalized adults.

Authors:  D W Bates; L L Leape; S Petrycki
Journal:  J Gen Intern Med       Date:  1993-06       Impact factor: 5.128

6.  Potential identifiability and preventability of adverse events using information systems.

Authors:  D W Bates; A C O'Neil; D Boyle; J Teich; G M Chertow; A L Komaroff; T A Brennan
Journal:  J Am Med Inform Assoc       Date:  1994 Sep-Oct       Impact factor: 4.497

Review 7.  Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.

Authors:  W N Patton; S B Duffull
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

8.  Relationship between medication errors and adverse drug events.

Authors:  D W Bates; D L Boyle; M B Vander Vliet; J Schneider; L Leape
Journal:  J Gen Intern Med       Date:  1995-04       Impact factor: 5.128

9.  A comparison of active surveillance programs including a spontaneous reporting model for phamacovigilance of adverse drug events in a hospital.

Authors:  Il Seon Yun; Myung Jin Koo; Eun Hye Park; Sung-Eun Kim; Jae-Hyun Lee; Jung-Won Park; Chein-Soo Hong
Journal:  Korean J Intern Med       Date:  2012-11-27       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.